AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

March 6, 2019

SAN DIEGO--(BUSINESS WIRE)--Mar 6, 2019--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. Eastern Time.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. To learn more, please visit www.odonate.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190306005771/en/

CONTACT: Odonate Therapeutics, Inc.

John Lemkey

Chief Operating Officer

858-731-8180

jlemkey@odonate.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Odonate Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 03/06/2019 04:30 PM/DISC: 03/06/2019 04:30 PM

http://www.businesswire.com/news/home/20190306005771/en